Researchers have discovered a way to predict whether patients with lung cancer will respond to expensive immunotherapy treatment in the latest breakthrough in personalised medicine.

University of Queensland researcher Arutha Kulasinghe studied lung biopsies from the tumours of almost 250 patients with non-small cell lung cancer across Australia, the United States and Europe.

Non-small cell lung cancer is the most common type, affecting almost 90 per cent of patients.

Working with scientists in the US and Melbourne, Associate Professor Kulasinghe used powerful microscopes and computers to analyse millions of cells within each sample.

"We wanted to find out if there were patterns in the tissues that were predictive of response or resistance to immunotherapies," he said.

The study is bei

See Full Page